top of page


Yogita Dhas.jpg

Content writer – Clinical

April 12, 2023

Summary "Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas."

Meningiomas are the most prevalent primary central nervous system tumor, with a prevalence of 170,000 cases in the United States. Maximal safe resection is the cornerstone of meningioma treatment, and...

jay darji.jpg

Content writer – Clinical

March 29, 2023

Summary "A hybrid CNN-GLCM classifier for detection and grade classification of brain tumor."

A tumor is a volume of irregular and abnormal cells affecting the function of nearby healthy cells in the human body. Meningioma is the most commonly occurring tumor in adults with high-risk factors...

Isha Shaw.jpg

Data analyst intern

March 07, 2023

Summary "Quality of YouTube videos on meningioma treatment using the DISCERN instrument."

Meningiomas are the most common type of primary brain tumor that arises from the brain or the spinal cord. Although the majority of meningiomas are benign, these tumors can cause problems as they grow...

Quality of YouTube videos on meningioma treatment using the DISCERN instrument.jpg
Vijay Padul, PhD.jpg

Sr. scientist – Omics

January 11, 2023

Summary "An effective integrated grading system for meningioma tumour grading that incorporates molecular features."

Meningioma is the most common primary intracranial tumor in the United States. There are approximately 35,000 new cases diagnosed every year. meningioma has an estimated population prevalence of approximately...


Content writer – Clinical

Novemebr 09, 2022

Summary "High frequency of psychosis in late-stage Parkinson's disease."

Parkinson’s disease (PD) is a neurological disorder observed mostly in elderly individuals. The symptoms include tremors, muscle stiffness, slow motion, and loss of balance. It is caused when neurons of the basal ganglia region...

Parkinson's disease.jpg
Connecting Dots

Get the latest updates

Join Celltalk!

Subscribe us today & receive latest updates on your mail !

bottom of page